Evidence map›Paper›PMID 42777002›Full record

ArticlePLoS pathogens2026

SARS-CoV-2 defective viral genomes from distinct genomic regions drive divergent interferon responses.

Justin W Brennan, Simone Spandau, Jiayu Xu, Xingjian Wang, Haley Aull, Gaochan Wang, Sarah Connor, Gloria S Pryhuber, Thomas J Mariani, Ruth Serra-Moreno and 2 more

Abstract read
In one paragraph

Article in PLoS pathogens, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Justin W BrennanDepartment of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York, United States of America.
Simone SpandauDepartment of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York, United States of America.
Jiayu XuDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
Xingjian WangDepartment of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York, United States of America.
Haley AullDepartment of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York, United States of America.
Gaochan WangDivision of Allergy, Immunology, and Rheumatology (AIR), Department of Medicine, University of Rochester Medical Center, Rochester, New York, United States of America.
Sarah ConnorDepartment of Pediatrics and Center for Children's Health Research, University of Rochester Medical Center, Rochester, New York, United States of America.
Gloria S PryhuberDepartments of Pediatrics and Environmental Medicine, University of Rochester Medical Center, Rochester, New York, United States of America.
Thomas J MarianiDepartment of Pediatrics and Center for Children's Health Research, University of Rochester Medical Center, Rochester, New York, United States of America.
Ruth Serra-MorenoDepartment of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York, United States of America.
Susan R WeissDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
Yan SunDepartment of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York, United States of America.ORCID https://orcid.org/0000-0002-5320-5793

Funding

BioRepository for INvestigation of Diseases of the Lung (BRINDL) - Phase IIIU01HL148861 · NHLBI · UNIVERSITY OF ROCHESTER · PI GLORIA S PRYHUBER · 2019 to 2026
$9.7M
The Human Lung BioMolecular Multi-Scale Atlas Program (HuBMAP-Lung)U54HL165443 · NHLBI · UNIVERSITY OF ROCHESTER · PI PRYHUBER, GLORIA S · 2022 to 2025
$8.0M
MERS coronavirus: antagonism of double-stranded RNA induced host response by accessory proteinsR01AI140442 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Susan R Weiss · 2018 to 2026
$5.1M
Multidisciplinary Training in Pulmonary ResearchT32HL171029 · NHLBI · UNIVERSITY OF ROCHESTER · PI Steve N Georas, Michael A O'Reilly · 2024 to 2026
$1.5M
NHLBI NIH HHS T32 HL171029NHLBI NIH HHS U01 HL148861NHLBI NIH HHS U54 HL165443NIAID NIH HHS R01 AI140442
6 · The paper itself

Abstract

Defective viral genomes (DVGs) are generated during the genomic replication of many RNA viruses. When produced early in infection or supplemented at the onset of infection, DVGs can attenuate viral pathogenesis by stimulating interferon responses and antagonizing wild type (WT) virus replication, highlighting their potential as antiviral therapeutics. However, during natural infection DVGs can exert both antiviral and proviral effects depending on their generation kinetics, species, and abundance, underscoring the need to better understand their roles in viral pathogenesis. Coronaviruses (CoVs) are RNA viruses that ubiquitously generate DVGs, yet the roles of DVGs during CoV infection are largely unknown. In a previous study we investigated SARS-CoV-2 DVG presence in vitro and in patient samples and discovered two major genomic hotspots (A and B) for their generation. Here, we first showed that overall DVG abundance tended to positively correlate with COVID-19 severity, with approximately 40% of DVGs originating from a specific genomic region designated hotspot B. Analysis of a publicly available single-cell RNA-seq dataset revealed that DVGs from hotspot B, but not hotspot A, were associated with elevated interferon responses, suggesting that DVGs derived from different genomic regions vary in their ability to stimulate innate immunity. To test this directly, we constructed two representative DVGs corresponding to hotspots A and B. Both DVGs suppressed the replication of co-infecting WT virus; however, only DVG-B induced robust interferon responses, exceeding those triggered by WT virus alone. This was further confirmed in human precision-cut lung slices. Mechanistically, DVG-B-derived dsRNA exhibited a distinct subcellular distribution compared to WT virus. Complementation with the nucleocapsid (N) partially restored dsRNA organization but did not alter the interferon response. Together, our findings demonstrate that DVGs arising from distinct genomic hotspots differentially regulate interferon responses, and N plays a unique role in regulating dsRNA distribution and interferon responses.

Indexed as

COVID-19Defective VirusesGenome, ViralInterferonsSARS-CoV-2AnimalsHumansRNA, ViralVirus ReplicationInterferonsRNA, Viral

Identifiers

PMID42777002
PMCPMC13626462

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.